Please assess the completion status of the following clinical trial:

Trial Title: Bendamustine and Rituximab Combination Therapy for Cold Agglutinin Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. CAD diagnosis defined by the combination of -~   1. Chronic hemolysis~  2. Cold agglutinin titer 64 or higher~  3. Positive direct antiglobulin test when performed with polyspecific antiserum, negative (or only weakly positive) with anti-IgG, and strongly positive with anti-C3d~2. The presence of a clonal B-cell lymphoproliferative disorder defined by -~   1. Monoclonal band by serum electrophoresis with immunofixation, and/or~  2. CD20 positive lymphocyte population with cellular kappa/lamda-ratio higher than 3.5 or less than 0.9, using flowcytometric immunophenotyping of bone marrow aspirates~3. Indication for therapy, i.e. significant anemia and/or considerable cold-induced circulatory symptoms~4. Written informed consent~Exclusion Criteria:~1. An aggressive lymphoma~2. Non-lymphatic malignant disease other than basal cell carcinoma of the skin. A history of probably cured cancer is not an exclusion criterion.~3. Known HIV infection~4. Acute or chronic hepatitis B or C~5. Liver failure or active parenchymal liver disease. Bilirubin levels higher than 51 mol/L (3.0 mg/dL) when due to hepatic impairment. Elevated serum bilirubin level due to hemolysis is not an exclusion criterion.~6. Pregnancy or breast-feeding~7. Patients of childbearing age who are not willing to use safe contraception during the entire study period and 6 months following its cessation~8. All contraindications to the study drugs will be regarded as exclusion criteria.~9. Age below 18 years~10. Inability to cooperate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment arm (Type: EXPERIMENTAL): Bendamustine, Rituximab

Based on this trial design, predict the completion outcome and termination type (if applicable).